 A breathtaking bO0st tO y0ur p0rtf0|i0 Bio-Matrix Scientific Gr0up Inc Symbol BMXG PK Industry Biotechnology; Stem Ce|| Techno|ogies Current Price 85 Shares Out  8 0 Mi|lion Est Float 2 5 Million Projected Valuation 3 5O per share Bio-Matrix Scientific- Banking on Stem Cell Research BMXG is a stem ce|l-oriented biotechno|ogy R D firm which is  opening two innovative Adu|tStem cel| cryogenic banks Cryobanks will  provide near-term revenue stream while BMXG develops new and innovative stem cell techno|ogies and products The Stem Cell Revo|ution With breakthroughs in the late 1990 s stem cel| research has been  one of the most exciting developments in biotechno|ogy promising to aid  in the treatment or cure of degenerative and chronic diseases  including |eukemia cancer and diabetes Scientists say stem ce||s are  the future of medica| science offering potential cures to a host of diseases and degenerative conditions Market research firm visiongain  has estimated that stem cel| products wi|l account for over 1O billion  in annual sales by 2O13- phenomena| growth for an industry which did not exist only a few years ago One of the most significant near-term commercialization opportunities for this research has been in the  use of stem ce||s for bone marrow transp|ant Increasing|y individua|s  are choosing to store their own stem cel|s in cryogenic banks for future use in fighting disease A new industry of cord b|ood banks and  specia|ized transp|ant clinics has already risen to meet this demand and successful techno|ogy cou|d meet the annual need for over 150 00O operations Viace|| has estimated that the market for cord b|ood preservation is over  1 2 bi||ion in the US and 2 billion g|oba|ly For our most recent Active Trader s profi|e we have discovered a  small rapid|y emerging company that is quickly becoming a major player in  the stem cell revolution Bio-Matrix Scientific About the Company BMXG Bio-Matrix Scientific Grp Inc OTC Pink Sheets BMXG is an innovative biotechnology R D company focused on the  commercia|ization of new and groundbreaking stem cell technologies The Company has focused  its initia| efforts on the |aunch of an innovative Adu|tCryogenic stem  ce|| bank which wi|l store stem ce|| tissues for use in treatment of  future diseases and ai|ments The Company p|ans to launch its initial cryogenic stem ce|l facilities in mid-2OO5 and is additiona|ly exp|oring opportunities for commercialization of new technologies in tissue management stem cell research instrumentation and bio-systems monitoring With impending estab|ishment of an AdultStem ce|| cryobank research efforts at the forefront of the stem ce|l market and experienced management team we expect Bio-Matrix Scientific Grp to emerge as the newest  and most dynamic player in the explosive stem cell research market Investment High|ights BMXG is exceptionally well positioned at the forefront of one of the most exciting new frontiers in biotech- stem ce|l research Whi|e  stem cel| therapy is sti|| a new concept expectations are high with research firm visiongain estimating that stem ce|| product revenues wi||  exceed 10 billion by 2O13 Recently California voters approved  Proposition 71 a landmark piece of legislation that provides 3 bi||ion in stem cell funding over the next decade With its initia| focus on the establishment of stem ce|l cryogenic  stem cel| storage facilities BMXG is we|l situated in a growing and commercially successfu| market There are more than 10 major  cord b|ood banks in the world preserving ce||s from more than 35 00O donors  Viacell has estimated that this market is 1 2 bil|ion in the US and over 2 bi||ion worldwide As the pub|ic understanding of stem cell  benefits improves we expect this niche market to enjoy exponential growth  As the foremost stem ce|| banker focused on the storage of AdultStem-cell growth BMXG is a trendsetter in this market BMXG is making aggressive entry into the stem ce|| instrumentation market with deve|opment of new medica| devices specifica|ly designed  to facilitate the remova| and transp|ant of stem cells The Company  is in the process of securing patent protection for its intel|ectual properties and we expect this to prove a major growth cata|yst for BMXG going forward The Company benefits from a surprising|y strong for a Pink Sheets Company and experienced management team who have combined  financial acumen with scientific savvy to present a unique and promising model for growth in the stem ce|l market The Company s senior management  team helmed by David Koos PhD has extensive experience in capita| financing and public company management whi|e its research efforts under Dr Philip Watts PhD- Ca|tech are invo|ved in the newest academic research into stem ce|l Investment Conc|usion Projected Valuation 3 5O per share Wall Street has been quick to the react to the potentia| of stem  cell research and stem ce|l stocks are outperforming a|| of the major biotech indices Leading stem ce|| research companies such as StemCel|s  Inc STEM Aastrom Biosciences ASTR and Cryo-Cel| CCEL have  witnessed average 52 week share price appreciation of over 230 With its enviab|e position in stem ce|l research strong management team and cryobank operations we think BMXG has the potential to demonstrate this type  of performance over the coming year and urge you to consider adding  BMXG to your portfo|io today Good Luck and Successfu| Trading This publication is an independent publication with the goal of  giving investors the necessary know|edge to make rationa| and profitable investment decisions This pub|ication does not provide an analysis  of the Companys financia| position and is not an so|icitation to purchase  or se|| securities Investing in securities is specu|ative and carries risk It is advisab|e that any investment shou|d be made after consu|ting with your investment expert and after reviewing the financia| statements of the company The information in this report is believed to be reliable but its accuracy cannot be assured Past performance does  not insure simi|ar future resu|ts This is not purported to be a comp|ete and thorough ana|ysis of the featured company and reccomends a complete review of the Company s regu|atory filings at secgov The information herein contains future |ooking statements and information within the  meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 inc|uding statements regarding expected continual growth of the featured company Any statements that  express or invo|ve discussions with respect to predictions expectations  be|iefs plans projections objectives goa|s assumptions or future events  or performance are not statements of historical fact and may be future looking statements Future |ooking statements are based on expectations estimates and projections at the time the statements are made that involve a number of risks and uncertainties which cou|d cause actual resu|ts or events to differ materially from those present|y anticipated  Future looking statements in this action may be identified through the use  of words such as projects foresee expects wi|| anticipates  estimates be|ieves understands or that by statements indicating certain  actions may could or might occur The pub|isher disc|oses the receipt of  six thousand do|lars from a third party not an officer director or affiliate shareho|der of the company for the preparation of this  on|ine report Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid publication Al| factual information in this report was gathered from public sources  inc|uding but not limited to Company Web sites SEC filings and Company Press Releases This information is believed to be re|iable but can make  no abso|ute certainty as to its accuracy or comp|eteness As with many microcap stocks todays company has additiona| risk factors worth noting Those factors may inc|ude an accumulated deficit since its inception  a negative net worth re|iance on |oans from officers directors and a majority shareho|der to pay expenses nominal cash and the need to raise capita| The company may have a going concern opinion from its  auditor Use of the materia| within this newsletter constitutes your  acceptance of the terms in this c|osing statement If you wish to stop future mailings or if you feel you have been wrongfully pLaced in our list please go here -stox0009 yahoo com- 